• 1
    Swarts, K. ( 2009) Genetic Disorders. Greenhaven Press, Farmington Hills, MI.
  • 2
    Barranger, J. A. andCabrera-Salazar, M. ( 2007) Lysosomal Storage Disorders. Springer, Berlin-Heidelberg.
  • 3
    Neufeld, E. F. andMuenzer, J. ( 2001) Mucopolysaccharidoses. In: The Metabolic and Molecular Bases of Inherited Disease( Scriver, C. R.,Beaudet, A. L.,Sly.W. S., andValle, D., eds.). pp. 34213452, McGraw-Hill Co., New York.
  • 4
    Węgrzyn, G.,Jakóbkiewicz-Banecka, J.,Narajczyk, M.,Wiśniewski, A.,Piotrowska, E., et al.( 2010) Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different? Med. Hypoth. 75, 605609.
  • 5
    Wraith, J. E. ( 2009) Enzyme replacement therapy for the management of the mucopolysaccharidoses. Int. J. Clin. Pharmacol. Ther. 47 ( Suppl 1), S63S65.
  • 6
    Beck, M. ( 2010) Therapy for lysosomal storage disorders. IUBMB Life 62, 3340.
  • 7
    Cotrim, A. P. andBaum, B. J. ( 2008) Gene therapy: some history, applications, problems, and prospects. Toxicol. Pathol. 36, 97103.
  • 8
    Schultz, M. L.,Tecedor, L.,Chang, M., andDavidson, B. L. ( 2011) Clarifying lysosomal storage diseases. Trends Neurosci. 34, 401410.
  • 9
    Jakóbkiewicz-Banecka, J.,Piotrowska, E.,Gabig-Cimińska, M.,Borysiewicz, E.,Słomińska-Wojewódzka, M., et al.( 2011) Substrate reduction therapies for mucopolysaccharidoses. Curr. Pharm. Biotechnol. 12, 18601865.
  • 10
    Roberts, A. L.,Thomas, B. J.,Wilkinson, A. S.,Fletcher, J. M., andByers, S. ( 2006) Inhibition of glycosaminoglycan synthesis using a rhodamine B in a mouse model of mucopolysaccharidosis type IIIA. Pediatr. Res. 60, 309314.
  • 11
    Roberts, A. L.,Rees, M. H.,Klebe, S.Fletcher, J. M., andByers, S. ( 2007) Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Mol. Genet. Metab. 92, 115121.
  • 12
    Roberts, A. L.,Fletcher, J. M.,Moore, L., andByers, S. ( 2010) Trans-generational exposure to low levels of rhodamine B does not adversely affect litter size or liver function in murine mucopolysaccharidosis type IIIA. Mol. Genet. Metab. 101, 208213.
  • 13
    Dziedzic, D.,Węgrzyn, G., andJakóbkiewicz-Banecka, J. ( 2010) Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease. Eur. J. Hum. Genet. 18, 200205.
  • 14
    Kaidonis, X.,Liaw, W. C.,Roberts, A. D.,Ly, M.,Anson, D., et al.( 2010) Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulfate storing mucopolysaccharidoses. Eur. J. Hum. Genet. 18, 194199.
  • 15
    Smith, R. A.,Miller, T. M.,Yamanaka, K.,Monia, B. P.,Condon, T. P., et al.( 2006) Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. 116, 22902296.
  • 16
    Juliano, R.,Alam, M. R.,Dixit, V., andKang H.( 2008) Mechanism and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res. 36, 41584171.
  • 17
    Węgrzyn, G.,Węgrzyn, A., andTylki-Szymańska, A. ( 2004) A general model for genetic regulation of turnover of glycosaminoglycans suggests a possible procedure for prediction of severity and clinical progress of mucopolysaccharidoses. Med. Hypoth. 62, 986992.
  • 18
    Piotrowska, E.,Jakóbkiewicz-Banecka, J.,Tylki-Szymańska, A.,Czartoryska, B.,Węgrzyn, A., et al.( 2009) Correlation between severity of mucopolysaccharidoses and combination of the residual enzyme activity and efficiency of glycosaminoglycan synthesis. Acta Paediatr. 98, 743749.
  • 19
    Pisano, M. M. andGreene, R. M. ( 1987) Epidermal growth factor potentiates the induction of ornithine decarboxylase activity by prostaglandins in embryonic palate mesenchymal cells: effects on cell proliferation and glycosaminoglycan synthesis. Dev. Biol. 122, 419431.
  • 20
    Akiyama, T.,Ishida, J.,Nakagawa, S.,Ogawara, H.,Watanabe, S., et al.( 1987) Genistein, a specific inhibitor of tyrosine-specific protein kinase. J. Biol. Chem. 262, 55925595.
  • 21
    Tsai, T. H. ( 2005) Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application. J. Chromatogr. A 1073, 317322.
  • 22
    Piotrowska, E.,Jakóbkiewicz-Banecka, J.,Barańska, S.,Tylki-Szymańska, A.,Czartoryska, B., et al.( 2006) Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur. J. Hum. Genet. 14, 846852.
  • 23
    Jakóbkiewicz-Banecka, J.,Piotrowska, E.,Narajczyk, M.,Barańska, S., andWęgrzyn, G. ( 2009) Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J. Biomed. Sci. 16, 26.
  • 24
    Arfi, A.,Richard, M.,Gandolphe, C., andScherman, D. ( 2010) Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones. J. Inherit. Metab. Dis. 33, 6167.
  • 25
    Kloska, A.,Jakóbkiewicz-Banecka, J.,Narajczyk, M.,Banecka-Majkutewicz, Z., andWęgrzyn, G. ( 2011) Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses. Metab. Brain Dis. 26, 18.
  • 26
    Friso, A.,Tomanin, R.,Salvalaio, M., andScarpa, M. ( 2010) Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br. J. Pharmacol. 159, 10821091.
  • 27
    Malinowska M.,Wilkinson, F. L.,Bennett, W.,Langford-Smith, K. J.,O'Leary, H. A., et al.( 2009) Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol. Genet. Metab. 98, 235242.
  • 28
    Malinowska, M.,Wilkinson, F. L.,Langford-Smith, K. J.,Langford-Smith, A.,Brown, J. R., et al.( 2010) Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One 5, e14192.
  • 29
    Jakóbkiewicz-Banecka.J.,Węgrzyn, A., andWęgrzyn, G. ( 2007) Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases. J. Appl. Genet. 48, 383388.
  • 30
    Piotrowska, E.,Jakóbkiewicz-Banecka, J.,Tylki-Szymańska, A.,Liberek, A.,Maryniak, A., et al.( 2008) The use of genistein-rich isoflavone extract in substrate reduction therapy for Sanfilippo disease: open-label, pilot study in 10 pediatric patients. Curr. Ther. Res. Clin. Exp. 69, 166179.
  • 31
    Kloska, A.,Bohdanowicz, J.,Konopa, G.,Tylki-Szymańska, A.,Jakóbkiewicz-Banecka, J., et al.( 2005) Changes in hair morphologyof mucopolysaccharidosis I patients treated with recombinant human α-L-iduronidase (laronidase, Aldurazyme). Am. J. Med. Genet. A 139, 199203.
  • 32
    Malinowska, M.,Jakóbkiewicz-Banecka, J.,Kloska, A.,Tylki-Szymańska, A., andCzartoryska, B. ( 2007) Abnormalities in the hair morphology of patients of same but not all types of mucopolysaccharidoses. Eur. J. Pediatr. 167, 203209.
  • 33
    Piotrowska, E.,Jakobkiewicz-Banecka, J.,Maryniak, A.,Tylki-Szymańska, A.,Puk, E., et al.( 2011) Two-year follow-up of Sanfilippo disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients. Med. Sci. Monit. 17, CR196CR202.
  • 34
    Delgadillo, V.,del Mar O'Callaghan, M.,Artuch, R.,Montero, R., andPineda, M. ( 2011) Genistein supplementation in patients affected by Sanfilippo disease. J. Inherit. Metab. Dis. 34, 10391044.
  • 35
    Malinova, V.,Węgrzyn, G., andNarajczyk, M. ( 2012) The use of elevated doses of genistein-rich soy extract in the gene expression-targeted isoflavone therapy (GET IT) for Sanfilippo disease patients. JIMD Rep., in press (DOI: 10.1007/8904_2011_87).
  • 36
    de Ruijter, J.,Valstar, M. J.,Narajczyk, M.,Węgrzyn, G.,Kulik, W., et al.( 2012) Genistein in Sanfilippo disease: a randomized controlled cross-over trial. Ann. Neurol. 71, 110120.
  • 37
    Marucha, J.,Tylki-Szymańska, A.,Jakóbkiewicz-Banecka, J.,Piotrowska, E.,Kloska, A., et al.( 2011) Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expression-targeted isoflavone therapy (GET IT). Am. J. Med. Genet. A 155, 22572262.
  • 38
    Piotrowska, E.,Jakóbkiewicz-Banecka, J., andWęgrzyn, G. ( 2010) Different amounts of isoflavones in various commercially available soy extracts in the light of gene expression-targeted isoflavone therapy. Phytother. Res. 24 ( Suppl 1), S109S113.
  • 39
    Szkudelska, K. andNogowski, L. ( 2007) Genistein—a dietary compound inducing hormonal and metabolic changes. J. Steroid Biochem. Mol. Biol. 105, 3745.
  • 40
    Rusin, A.,Krawczyk, Z.,Grynkiewicz, G.,Gogler, A.,Zawisza-Puchałka, J., et al.( 2010) Synthetic derivatives of genistein, their properties and possible applications. Acta Biochim. Pol. 57, 2334.
  • 41
    Węgrzyn, G.,Jakóbkiewicz-Banecka, J.,Gabig-Cimińska, M.,Piotrowska, E.,Narajczyk, M., et al.( 2010) Genistein: a natural isoflavone with a potential for treatment of genetic diseases. Biochem. Soc. Trans. 38, 695701.
  • 42
    Hamano, K.,Hayashi, M.,Shioda, K.,Fukatsu, R., andMizutani, S. ( 2008) Mechanisms of neurodegeneration in mucopolysacchridoses II and IIIB: analysis of human brain tissue. Acta Neuropathol. 115, 547559.
  • 43
    Villani, G. R.,Gargiulo, N.,Faraonio, R.,Castaldo, S.,Gonzalez, Y., et al.( 2007) Cytokines, nuerotrophins, and oxidative stress in brain disease from mucopolysaccharidosis IIIB. J. Neurosci. Res. 85, 612622.
  • 44
    Villani, G. R.,Di Domenico, C.,Musella, A.,Cecere, F.,Di Napoli, D., et al.( 2009) Mucopolysaccharisosis IIIB: oxidative damage and cytotoxic cell involvement in the neuronal pathogenesis. Brain Res. 1279, 99108.
  • 45
    Ohmi, K.,Kudo, L. C.,Ryazantsev, S.,Zhao, H. Z.,Karsten, S. L., et al.( 2009) Sanfilippo syndrome type B, a lysosomal storage disease, is also a tauopathy. Proc. Natl. Acad. Sci. U.S.A. 106, 83328337.
  • 46
    Bang, O. H.,Hong, H. S.,Kim, D. H.,Kim, H.,Boo, J. H., et al.( 2004) Neuroprotective effect of genistein against beta amyloid-induces neurotoxicity. Neurobiol. Dis. 16, 2128.
  • 47
    Liang, H. W.,Qiu, S. F.,Shen, J.,Sun, L. N., andWang, J. Y. ( 2008) Genistein attenuates oxidative stress and neuronal damage following transient global cerebral ischemia in rat hippocampus. Neurosci. Lett. 438, 116120.
  • 48
    Valles, S. L.,Dolz-Gaiton, P.,Gambini, J.,Borras, C.,Loret, A. L., et al.( 2010) Estradiol or genistein prevent Alzheimer's disease-associated inflammation correlating with an increase PPAR gamma expression cultured astrocytes. Brain Res. 1312, 138144.
  • 49
    Kajta, M.,Domin, H.,Grynkiewicz, G., andLason, W. ( 2007) Genistein inhibits glutamate-induced apoptotic processes in primary neuronal cell cultures: an involvement of aryl hydrocarbon receptor and estrogen receptor/glycogen synthase kinase-3beta intracellular signaling pathway. Neuroscience 145, 592604.
  • 50
    Chindewa, R.,Lapanantasin, S.,Sanvarinda, Y., andChongthammakun, S. ( 2007) Genistein effects on synaptophysin expression in rat hippocampal neurons. Ann. Microsc. 7, 95101.